Neurology Central

First disease-modifying therapy approved for pediatric multiple sclerosis: industry news round-up

0
This week’s industry news round-up reveals the latest updates including neuroblastoma, DUB inhibitors for neurodegenerative disorders and the first disease-modifying therapy for pediatric multiple sclerosis. Find out more about our selection of the highlights below.
Our pick of the highlights include:
  • NICE issues draft guidance against EUSA Pharma’s neuroblastoma drug Qarziba®
  • Multi-year collaboration to develop DUB inhibitors for the treatment of neurodegenerative diseases
  • First disease-modifying therapy approved for pediatric multiple sclerosis
    Restricted Content / Members Only

    You cannot view this content because It is available to members only. Please or Register to view this area.

Share: